Fineline Cube

Follow:
14422 Articles
Zennova & Rapafusyn Forge BioCarier‑Powered RapaGlue Collaboration – 2025
CompanyDeals

Zennova & Rapafusyn Forge BioCarier‑Powered RapaGlue Collaboration – 2025

Boehringer Ingelheim & Sino Biopharma Secure Conditional Approval for Zongertinib in China
CompanyDrug

Boehringer Ingelheim & Sino Biopharma Secure Conditional Approval for Zongertinib in China

Innovent Biologics Revenue Soars 50% in H1 2025 – Oncology Growth Fuels GLP‑1 Expansion
Company

Innovent Biologics Revenue Soars 50% in H1 2025 – Oncology Growth Fuels GLP‑1 Expansion

NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed
Policy / Regulatory

NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed

HarbourBioMed Reports 327 % Revenue Surge, Launches HCAb‑Based Élancé Therapeutics
Company

HarbourBioMed Reports 327 % Revenue Surge, Launches HCAb‑Based Élancé Therapeutics

Santen Receives Boao Lecheng Approval for RYJUSEA – A Preservative‑Free Atropine Eye Drop for Pediatric Myopia
CompanyDrug

Santen Receives Boao Lecheng Approval for RYJUSEA – A Preservative‑Free Atropine Eye Drop for Pediatric Myopia

Anglikang Secures Exclusive Rights to Yafei’s IMD‑1005 in China
CompanyDeals

Anglikang Secures Exclusive Rights to Yafei’s IMD‑1005 in China

RemeGen’s Telitacicept Hits Primary Endpoint in Phase III IgA Nephropathy Trial
CompanyDrug

RemeGen’s Telitacicept Hits Primary Endpoint in Phase III IgA Nephropathy Trial

ImmuneOnco Secures $5 M Milestone from Instil Bio, Strengthening Axion Bio Collaboration
CompanyDeals

ImmuneOnco Secures $5 M Milestone from Instil Bio, Strengthening Axion Bio Collaboration

Shandong Boan Biotechnology Reports 8% YoY Revenue Growth, 3‑Year Profit Trend
Company

Shandong Boan Biotechnology Reports 8% YoY Revenue Growth, 3‑Year Profit Trend

HitGen’s 2025 H1 Report Shows 16.58% Revenue Growth and 391% Profit Surge
Others

HitGen’s 2025 H1 Report Shows 16.58% Revenue Growth and 391% Profit Surge

Changchun High Files GenSci134 Clinical Trial for Growth Hormone Deficiency
CompanyDrug

Changchun High Files GenSci134 Clinical Trial for Growth Hormone Deficiency